Publications by authors named "J Herrstedt"

Claim this Profile
Q
Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel.
Dana M Chase, Jørn Herrstedt, Eirwen M Miller, Lucy Gilbert, Oleksandr Zub

Int J Gynecol Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and antiemetic efficacy of weekly administration of netupitant/palonosetron plus dexamethasone during 5 weeks of concomitant chemo-radiotherapy-the DANGER-emesis study.
Sofie S Detlefsen, Ditte S Andersen, Anja Ø Knudsen, Trine J Nøttrup, Sören Möller, Jørn Herrstedt

Support Care Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety.
Ursula A Matulonis, Jørn Herrstedt, Amit Oza, Sven Mahner, Andrés Redondo

Gynecol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
Matthew A Powell, David Cibula, David M O'Malley, Ingrid Boere, Mark S Shahin, Jørn Herrstedt

Gynecol Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, pharmacodynamics, safety, and tolerability of dopamine-receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting.
Adile Orhan, Carolyn Nguyen, Alexandre Chan, Jørn Herrstedt

Expert Opin Drug Metab Toxicol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis